期刊
AMERICAN JOURNAL OF HYPERTENSION
卷 22, 期 1, 页码 41-45出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/ajh.2008.314
关键词
-
资金
- National Heart, Lung and Blood Institute [RO1 HL65311]
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065311, R01HL093149] Funding Source: NIH RePORTER
BACKGROUND Previous studies have shown that the presynaptic alpha(2B)-adrenoceptor subtype in the central nervous system has a sympathoexcitatory function and its activation leads to a hyperadrenergic hypertensive state. The purpose of this project was to develop a novel hyperadrenergic model, a transgenic (TG) mouse model with brain-selective overexpression of the alpha(2B)-adrenergic receptor (alpha(2B)-AR). METHODS We used Southern blot analysis to confirm transgene, real-time PCR to assess gene expression, western Blot analysis and immunohistology to assess protein expression and localization in brain areas. Indirect blood pressure (BP) and heart rate were recorded. RESULTS In TG mice there was a 1.8-fold increase in alpha(2B)-AR protein expression compared to wild-type (WT) mice. Immunostaining of brain sections revealed that concentration of alpha(2B)-AR was much more pronounced in TG than in WT mice. Systolic BP at 8 weeks of age was significantly elevated in TG 130+/-6 mm Hg, compared with WT control nontransgenic littermates of the same age 107+/-7 mmHg, (P<0.05), indicating that the TG mice had indeed developed hypertension. CONCLUSIONS We have therefore documented that overexpression of the alpha(2B)-AR gene leads to increased production of alpha(2B)-AR protein in brain regions known to regulate central sympathetic outflow, thus resulting in sustained BP elevation. This is a unique model of experimental hypertension driven purely by overexpression of the alpha(2B)-AR that would result in an overactive sympathetic system and would be suitable for testing the pharmacologic properties of potential therapeutic agents.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据